One possibility that could explain these discrepancies is the interface of Eph receptors with downstream networks that regulate tumorigenicity, such as that between EphB3 and the PP2A/RACK1/Akt axis in lung cancer [50], [51]. The gene discussed is PTPA; the disease is lung cancer.